AMG 745 in Subjects With Age-associated Muscle Loss

2014-08-27 03:19:25 | BioPortfolio


Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Age-associated Muscle Loss


AMG 745 0.3 mg/kg, AMG 745 1.0 mg/kg, AMG 745 3.0 mg/kg, Placebo


Not yet recruiting



Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:19:25-0400

Clinical Trials [1513 Associated Clinical Trials listed on BioPortfolio]

Muscle Loss and Fatigue as a Consequence of Radiotherapy

This study examines the extent of systemic muscle loss and the degree of fatigue experienced by breast cancer patients undergoing radiotherapy. This study seeks to identify whether muscle ...

The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism

This study will determine the effects of supplementing beta-hydroxy-beta-methylbutyrate (HMB) on body composition and strength changes during weight loss. When overweight and obese persons...

Prevalence of Sarcopenia and Its Geriatric Features

The goal of this study is to determine the prevalence of sarcopenia in a geriatric hospital ward. Sarcopenia is defined by a loss of muscle mass, loss of muscle strength and loss of muscl...

Effects of 14-days of HMB-free Acid on Changes in Muscle During 4-days of Survival Training

Sustained high-intensity activity, such as survival training with little nourishment available, can result in a loss of muscle performance. This study will examine the effects of a nutrit...

Two Weeks of Reduced Activity and Skeletal Muscle Health in Older Men

Muscle size declines at around 0.5-1% per year after 50 years of age, with muscle strength declining up to twice as fast as muscle size. This may eventually lead to loss of independence if...

PubMed Articles [8882 Associated PubMed Articles listed on BioPortfolio]

Eccentric Overload Muscle Damage is Attenuated By a Novel Angiotensin- (1-7) Treatment.

The development of new strategies to attenuate exercise-induced muscle damage may be helpful for training regimens. The aim of this study was to determine whether a oral formulation of angiotensin Ang...

Myosteatosis is associated with skeletal muscle volume loss in patients with chronic liver disease.

Severe muscle volume loss is a recognized negative prognostic factor in patients with chronic liver disease. However, the effect of skeletal muscle fat deposition, referred to as myosteatosis on muscl...

Impact of muscle atrophy on bone metabolism and bone strength: implications for muscle-bone crosstalk with aging and disuse.

Bone fractures in older adults are often preceded by a loss of muscle mass and strength. Likewise, bone loss with prolonged bed rest, spinal cord injury, or with exposure to microgravity is also prece...

The age-related loss of skeletal muscle mass and function: measurement and mechanisms of muscle fibre atrophy and muscle fibre loss in humans.

Age-related loss of skeletal muscle mass and function, sarcopenia, is associated with physical frailty and increased risk of morbidity (chronic diseases), in addition to all-cause mortality. The loss ...

Cachexia and sarcopenia in chronic heart failure : Change in muscle strength and muscle structure.

Alterations to the body composition, i.e. the makeup of skeletal muscle, fat and bone density, are frequent in heart insufficiency. Their prevalence and clinical consequences are often underestimated....

Medical and Biotech [MESH] Definitions

A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

Inflammation of the PERICARDIUM that is characterized by the fibrous scarring and adhesion of both serous layers, the VISCERAL PERICARDIUM and the PARIETAL PERICARDIUM leading to the loss of pericardial cavity. The thickened pericardium severely restricts cardiac filling. Clinical signs include FATIGUE, muscle wasting, and WEIGHT LOSS.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)

More From BioPortfolio on "AMG 745 in Subjects With Age-associated Muscle Loss"

Quick Search


Relevant Topics

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Searches Linking to this Trial